Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 26 of 28.
Oct 2008
27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 55971.93 lacs for quarter ending on 30-SEP-2008 against Rs. 37489.85 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 11736.01 lacs for the quarter ending on 30-SEP-2008 against Rs. 7512.64 lacs for the quarter ending on 30-SEP-2007.27 Oct · Updates
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding Management Discussion and Analysis for the Second quarter of the financial year 2008-09 ended September 30, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 41982.93 lacs for half year ending on 30-SEP-2008 against Rs. 54221.38 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 12372.24 lacs for the half year ending on 30-SEP-2008 against Rs. 11245.61 lacs for the half year ending on 30-SEP-2007.27 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 27, 2008, titled "Glenmark posts consolidated revenue growth of 49.30% and Net profit growth of 56.21% for Q2 FY09; Consolidated revenue at Rs. 5597.19 Mn and Net Profit at Rs. 1173.60 Mn". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 22585.42 lacs for quarter ending on 30-SEP-2008 against Rs. 27926.68 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 6688.67 lacs for the quarter ending on 30-SEP-2008 against Rs. 6386.38 lacs for the quarter ending on 30-SEP-2007.24 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 24, 2008, titled "Further clinical trials in Osteoarthritis pain suspended for GRC 6211". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Board meeting
To consider and approve the Un-audited Financial results for the second quarter/ half year ended September 30, 2008.13 Oct · Issue of Stock Options
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "At the meeting of the members of the Compensation Committee held on 10th October, 2008 the Company has issue 12,40,000 stock options to the permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches".13 Oct · Proceedings
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the proceedings of the Deemed EGM held on October 06, 2008 towards declaration of the results of Postal Ballot. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Operation Committee Meeting held today i.e. on October 10, 2008 allotted 72,400 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.10 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 10, 2008, titled "Phase II-b trials for Oglemilast(GRC 3886) in Asthma initiated". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "Pursuant to the notice dated August 11, 2008, the shareholders of Glenmark Pharmaceuticals Ltd. have approved through postal ballot the Resolutions at the deemed Extraordinary General Meeting (EGM) held on October 06, 2008". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Oct · Meeting
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 26, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
25 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 25, 2008, titled "Glenmark dermatology line expands with recent U.S. FDA approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 11, 2008, titled " Glenmark to initiate Phase I studies for GBR 500 by filing its IND application with the US-FDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Sep · Disclosure
HSBC Global Asset Management (Hong Kong) Limited, on behalf of HSBC Global Asset Management (Singapore) Limited has informed the Exchange that HSBC Global Investment Funds a/c HSBC Global Investment Funds (Mauritius) Limited (the "Fund") managed by HSBC Global Asset Management (Singapore) Limited being the investment adviser of the Fund, currently hold 4.709% of the paid up share capital or voting capital of Glenmark Pharmaceuticals Ltd. Further, the Company has submitted to the Exchange a copy of the disclosure under the SEBI (Substantial Acquisition of Shares and Take-overs) Regulations. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Sep · Allocation of Stock Options
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Operation Committee Meeting held on September 5, 2008 alloted 6,300 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.2 Sep · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that 1)The Annual General Meeting of the Company will be held on September 26, 2008. 2) The Register of Members and Transfer Book of the Company shall remain closed from September 22, 2008 to September 26, 2008 (both days inclusive).1 Sep · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that pursuant to the provisions of section 192A(2) of the Act read together with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001, the consent of the shareholders to be obtained by means of Postal Ballot. (1) Consent pursuant to the provisions of section 372A to make loans, give guarantees upto a limit not exceeding Rs.4000 Crores. (2) Consent pursuant to section 293(1)(d) to borrow upto Rs.4000 Crores. (3) Consent pursuant to section 293(1)(a) of the Companies Act, to create a mortgage and / or charge over all the movable and immovable properties of the Company. The Company has appointed Mr. Surjan Singh Rauthan, Practicing Company Secretary, Mumbai, as the Scrutinizer for conducting the Postal Ballot in a fair and transparent manner. The Postal Ballot Form duly completed and signed should reach the Scrutinizer on or before the close of working hours on September 29, 2008. The Scrutinizer shall submit his report to the Chairman of the Company after the completion of the scrutiny and the results of the Postal Ballot shall be announced on October 06, 2008. A copy of the notice of postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
12 Aug · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Meeting held today i.e. on August 11, 2008 allotted 1000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003".
Jul 2008
28 Jul · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Meeting held today i.e. on July 28, 2008 allotted 81,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003".28 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 28, 2008, titled "Glenmark posts consolidated revenue growth of 29.78% and Net profit growth of 101.88 % for Q1FY09; Consolidated revenue at Rs. 4664.50 Mn and Net Profit at Rs. 1153.76 Mn". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jul · Updates
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding Management Discussion and Analysis Report for the first quarter of the financial year 2008-09 ended June 30, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 19397.51 lacs for quarter ending on 30-JUN-2008 against Rs. 26294.7 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 5683.57 lacs for the quarter ending on 30-JUN-2008 against Rs. 4859.24 lacs for the quarter ending on 30-JUN-2007.28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 46082.49 lacs for quarter ending on 30-JUN-2008 against Rs. 35135.66 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 11537.68 lacs for the quarter ending on 30-JUN-2008 against Rs. 5715.13 lacs for the quarter ending on 30-JUN-2007.18 Jul · Board meeting
Meeting on 28 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”15 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 15, 2008, titled "Glenmark's molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, to enter Phase I trials; GRC 10693 is Glenmark's fifth molecule to enter clinical trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Compensation Committee of the Company at its meeting held on July 09, 2008 has cancelled 2,82,500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company. Further, the Compensation Committee has issued 1,93,000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re. 1/- each in one or more tranches.2 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 02, 2008, titled "Glenmark establishes a new company in Poland and acquires a product portfolio of 7 established brands, Acquistion will help Glenmark accelerate its Polish business". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2008
27 Jun · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company at its operation Committee Meeting held on June 27, 2008 allotted 30,600 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.20 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 20, 2008, titled "Glenmark Generics Launches Trandolapril Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jun · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated June 09, 2008 that :- "At the meeting of the Operations Committee of the Board of Directors held today , the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 7,500,000 into 1,293,706 Equity Shares at a price of Rs. 253.11 per share of face value Rs. 1/- each out of US$ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".
May 2008
30 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 30, 2008, titled "Glenmark Generics receives three ANDA approvals - Portfolio of 32 products for the US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 May · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company at its Operations Committee Meeting held today i.e. May 29, 2008 allotted 57,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003".5 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 05, 2008, titled "Glenmark launches topical antifungal cream - Onabet". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
28 Apr · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of Management Discussion & Analysis for fourth quarter/year of the Financial Year 2007-08 ended March 31st, 2008 and a copy of the press release dated April 28, 2008 titled "Glenmark posts a consolidated revenue growth of 62.56 per cent and consolidated revenues of Rs. 5822.35 million for Q4 FY08". A copies of the Management Discussion & Analysis and Press Release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 137269.08 lacs for year ending on 31-MAR-2008 against Rs. 80263.81 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 38902.38 lacs for the year ending on 31-MAR-2008 against Rs. 13480.44 lacs for the year ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 39689.78 lacs for quarter ending on 31-MAR-2008 against Rs. 27479.32 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 13014.09 lacs for the quarter ending on 31-MAR-2008 against Rs. 6256.32 lacs for the quarter ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 57269.58 lacs for quarter ending on 31-MAR-2008 against Rs. 33907.84 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 21896.32 lacs for the quarter ending on 31-MAR-2008 against Rs. 6325.83 lacs for the quarter ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 197834.2 lacs for year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 63125.97 lacs for the year ending on 31-MAR-2008.19 Apr · Board meeting
To consider and approve the Audited Financial Results for the 4th Quarter/Year ended March 31, 2008.10 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 10, 2008, titled "Glenmark completes preclinical development for initiating Phase I trials for GBR 500 - a monoclonal antibody for inflammation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2008, titled "Glenmark implements Business Re-organisation; Begins a new era of accelerated growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
17 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 17, 2008, titled "Glenmark launches Clobetasol from its niche dermatology pipeline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 13, 2008, titled "Glenmark launches Nabumetone and Hydroxyzine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that regarding a press release dated March 4, 2008, titled "Glenmark establishes presence in Romania". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
29 Feb · Allotment of shares
Glenmark Pharmaceuticals Ltd. had informed the Exchange that the Board of Directors of the Company, at its meeting held on February 29, 2008 allotted 1,08,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003. The Company has now informed the Exchange that inadvertently Company had mentioned as " Board of Directors at their meeting held on February 29, 2008 have allotted the 1,08,800 shares " Whereas the Operations Committee of the Board have at their meeting done the allotment on February 29, 2008".29 Feb · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on February 29, 2008 allotted 1,08,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.28 Feb · Meeting
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the proceedings of the Deemed EGM held on February 5,2008 for declaring the results of Postal Ballot.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 21, 2008, titled "Glenmark's molecule for Rheumatoid Arthritis-GRC 4039, enters Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.